trending Market Intelligence /marketintelligence/en/news-insights/trending/gLK7lQvuclSUxw-MfdX44g2 content esgSubNav
In This List

AbbVie wins reversal of $150M verdict in testosterone therapy case

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


AbbVie wins reversal of $150M verdict in testosterone therapy case

A U.S. District Judge in Chicago reversed a verdict against AbbVie Inc. in a lawsuit by a man who alleged that the company fraudulently misrepresented the risks of AndroGel, a testosterone replacement drug, Reuters reported.

Judge Matthew Kennelly in Chicago said the findings of the jury that held the company responsible were "logically incompatible," the news outlet reported.

A jury had previously ruled in favor of Oregon resident Jesse Mitchell, awarding him $150 million in punitive damages but nothing in compensatory damages. It concluded that AbbVie was not negligent or strictly liable for a heart attack suffered by the plaintiff after taking the drug, but said the company falsely marketed AndroGel.

"The irreconcilable conflict between the jury's finding of liability on the fraudulent misrepresentation claim and award of zero compensatory damages requires a new trial on this claim," Kennelly wrote.

Kennelly's ruling erased the punitive damages award, Reuters reported. A new trial is now scheduled for March 5.